Short answer
Stoke Therapeutics, Inc. (STOK) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the quarter ended September 30, 2026.
Stoke Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Investors should review the accompanying press release for reported financial figures and operating updates
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 EMPEROR enrollment complete at 162 patients, with data readout anticipated Q3 2027 and U.S. NDA planned H2 2027
- Approximately 110 patients reached Week 28, the primary seizure endpoint, while no patients have discontinued treatment
- FDA alignment supports four-domain Vineland-3 cognition and behavior analysis, potentially strengthening the regulatory package
- Cash, equivalents and marketable securities $358.8M, expected to fund operations into early 2028
- Q3 net loss widened to $73.6M from $38.3M, with R&D rising to $59.8M and SG&A to $28.7M for clinical and launch preparation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Stoke Therapeutics, Inc. 8-K filings
Get the next STOK 8-K as it lands
Follow STOK for push alerts, or ask the research agent what this filing means.